论文部分内容阅读
目的:观察左卡尼汀与参麦注射液联合提高缺血性心脏病性心力衰竭的有效性和安全性。方法:选取2010年2月—2014年2月在我院心脑血管科有缺血性心脏病性心力衰竭的住院病人326例,按是否愿意接受左卡尼汀联合参麦注射液分为试验组170例和对照组156例,两组均予调脂、抗血小板聚集、抗心肌缺血及抗心力衰竭治疗。试验组在上述治疗的基础上给予参麦注射液和左卡尼汀静滴,连续治疗2 W后评价效果,通过多普勒超声测量两组研究对象心功能指标。结果:试验组的LVPWs、LVPWTd、IVSTd、IVSTs较对照显著降低,且两组差异具有统计学意义(P<0.05)。在心脏功能性评价,试验组SV、E、A较对照组明显升高,且两组差异具有统计学意义(P<0.05)。结论:左卡尼汀与参麦注射液联合能有效改善缺血性心脏病性心力衰竭的心脏功能。
Objective: To observe the efficacy and safety of levocarnitine and shenmai injection in improving ischemic heart disease. Methods: From February 2010 to February 2014 in our hospital cardiology and cerebral vascular disease with ischemic heart disease in 326 cases of hospitalized patients, according to whether they are willing to accept the levocarnitine combined Shenmai injection into the test 170 cases in control group and 156 cases in control group. Both groups were given lipid-lowering, anti-platelet aggregation, anti-myocardial ischemia and anti-heart failure treatment. The experimental group was given Shenmai injection and levocarnitine intravenously on the basis of the above treatment, and the effect was evaluated after continuous treatment for 2 weeks. The cardiac function indexes of two groups of subjects were measured by Doppler ultrasound. Results: The LVPWs, LVPWTd, IVSTd and IVSTs in the experimental group were significantly lower than those in the control group (P <0.05). In the functional evaluation of the heart, SV, E, A in the experimental group were significantly higher than those in the control group, and the differences between the two groups were statistically significant (P <0.05). Conclusion: L-carnitine combined with Shenmai Injection can effectively improve the cardiac function in patients with ischemic heart disease.